Duration of immunotherapy - should we continue ad infinitum?

Area of Science:

• Oncology
• Immunotherapy
• Cancer Treatment

Background:

• The optimal duration for cancer immunotherapy remains an open question in clinical practice.
• Maturing survival data from early immunotherapy trials are providing insights into long-term efficacy.
• Understanding response durability post-treatment is crucial for optimizing patient care.

Purpose of the Study:

• To discuss the appropriate duration of immunotherapy for patients with melanoma.
• To comment on immunotherapy treatment duration in non-small cell lung cancer.
• To offer clinical guidance supporting the discontinuation of immunotherapy when appropriate.

Main Methods:

• Review of survival data from completed immunotherapy clinical trials.
• Analysis of response durability in patients with melanoma and non-small cell lung cancer.
• Expert commentary and synthesis of evidence to inform practice guidance.

Main Results:

• Evidence suggests that durable responses can be achieved after immunotherapy discontinuation in select cancer types.
• Specific survival data indicate potential for long-term benefit post-cessation of treatment.
• The findings support a re-evaluation of fixed treatment durations.

Conclusions:

• Immunotherapy treatment duration requires careful consideration based on emerging survival data.
• Discontinuation of immunotherapy may be a viable strategy for some melanoma and non-small cell lung cancer patients.
• Practice guidance is needed to support informed decisions regarding treatment cessation.